We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

REGENXBIO (NASDAQ:RGNX) Falls 21% Pre-Market on FDA Clinical Hold

REGENXBIO Inc. (NASDAQ:RGNX) shares dropped sharply in pre-market trading after the U.S. Food and Drug Administration placed a clinical hold on RGX-121, the company's investigational gene therapy for Mucopolysaccharidosis type II, also known as Hunter Syndrome. The hold followed the discovery of asymptomatic spine …

Nitish Kishor | 24 August 2026

Why Is Atrium Therapeutics (NASDAQ:RNA) Falling Pre-Market Today?

Atrium Therapeutics, Inc. (NASDAQ:RNA) shares fell in pre-market trading following the company's disclosure of inducement equity grants awarded to a newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The grants, a standard practice for attracting talent at growing biotechnology companies, …

Nitish Kishor | 24 August 2026

This Nasdaq Parkinson's Stock Slides 5% Pre-Market Even After National TV Spotlight

BioVie Inc. (NASDAQ:BIVI) shares declined in pre-market trading even after the company was featured in a Bloomberg Television broadcast highlighting its investigational Parkinson's disease therapy, bezisterim. The segment, distributed through a sponsored financial media platform, spotlighted the company's Phase 2 SUNRISE-PD trial results alongside …

Nitish Kishor | 24 August 2026

Biomea Fusion (NASDAQ:BMEA) Rises 8% Pre-Market on Trial Enrollment Milestone

Biomea Fusion, Inc. (NASDAQ:BMEA) shares rose in pre-market trading after the company announced completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II trial evaluating its lead candidate icovamenib in patients with insulin-deficient type 2 diabetes who remain inadequately controlled on standard-of-care therapies.

Nitish Kishor | 24 August 2026

This Nasdaq TechBio Stock Pulls Back Pre-Market After Sharp Multi-Week Rally

Caris Life Sciences, Inc. (NASDAQ:CAI) shares pulled back modestly in pre-market trading, giving back a small portion of a powerful multi-week rally that has taken the stock roughly 65% to 73% higher off its May lows. The pullback follows an August 5 earnings report …

Nitish Kishor | 24 August 2026

GeoVax Labs (NASDAQ:GOVX) Rises 8% Pre-Market Ahead of CEO Conference Appearance

GeoVax Labs, Inc. (NASDAQ:GOVX) shares rose in pre-market trading ahead of Chairman, President and Chief Executive Officer David Dodd's participation in the 2026 Georgia Life Sciences Summit, scheduled for August 25 and 26 in Sandy Springs, Georgia. Dodd, a former chair of Georgia Life …

Nitish Kishor | 24 August 2026

This NYSE American Oncology Stock Slides 11% Pre-Market Ahead of 1-for-7 Reverse Split

Kairos Pharma, Ltd. (NYSE American:KAPA) shares fell in pre-market trading ahead of the company's previously announced 1-for-7 reverse stock split, which is set to become effective at 12:01 a.m. Eastern Time on September 1, 2026. Shares are expected to begin trading on a split-adjusted …

Nitish Kishor | 24 August 2026

LifeVantage (NASDAQ:LFVN) Falls 9% Pre-Market Ahead of Fiscal Fourth-Quarter Earnings

LifeVantage Corporation (NASDAQ:LFVN) shares fell in pre-market trading ahead of the company's fiscal fourth-quarter and full fiscal year 2026 results, scheduled for release after the market closes on Thursday, August 27, with a conference call to follow the same afternoon. The pre-market move comes …

Nitish Kishor | 24 August 2026

908 Devices (NASDAQ:MASS) Rises 8% Pre-Market as Momentum Builds

908 Devices Inc. (NASDAQ:MASS) shares rose in pre-market trading, extending recent momentum ahead of the company's scheduled presentation at the 17th Annual Midwest IDEAS Investor Conference on August 26. Chief Executive Officer and Co-founder Kevin J. Knopp and Chief Financial Officer Joe Griffith are …

Nitish Kishor | 24 August 2026

Why Is AEON Biopharma (NYSE American:AEON) Rising 6% Pre-Market Today?

AEON Biopharma, Inc. (NYSE American:AEON) shares rose in pre-market trading after the company announced final, expanded primary structure results supporting the molecular similarity of its lead candidate ABP-450 to BOTOX. The expanded analysis achieved 98% sequence coverage of the active botulinum neurotoxin, up from …

Nitish Kishor | 24 August 2026
Support

Hi! How can we help you today?

Loading…